Cardiff Oncology (CRDF) investor relations material

Introduction and agenda

• Focused on evolving treatment landscape in first-line RAS mutated metastatic colorectal cancer and recent clinical data for onvansertib, a selective PLK1 inhibitor, in combination with standard of care therapy.

• Discussed study design, endpoints, and patient characteristics for an ongoing phase II trial in first-line metastatic CRC.

KOL background and credentials

• Dr. Heinz-Josef Lenz: Professor at USC, deputy cancer center director, co-director of drug development, over 650 publications, key contributor to multiple approved CRC therapies.

• Dr. Scott Kopetz: Professor and deputy chair at MD Anderson, leader in translational oncology, principal investigator for GI SPORE, over 400 publications, advanced standards for BRAF mutated CRC.

Market insights and analysis

• First-line RAS mutated metastatic CRC has seen limited progress, with a significant unmet need for new therapies.

• Current standard of care remains largely unchanged for decades, with most patients receiving chemotherapy backbones plus bevacizumab.

• Only a small subset of patients benefit from targeted therapies; majority still lack effective first-line options.